Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
June 24, 2023 05:30 ET
|
Vir Biotechnology, Inc.
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
June 07, 2023 02:13 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio...
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
June 05, 2023 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to...
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
May 17, 2023 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19,...
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
May 15, 2023 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer....
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
May 11, 2023 08:30 ET
|
Vir Biotechnology, Inc.
– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ...
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:05 ET
|
Vir Biotechnology, Inc.
– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza – – Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company...
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
May 03, 2023 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at...
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
May 02, 2023 09:00 ET
|
Vir Biotechnology, Inc.
– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector – – Long-standing partnership...
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head...